Rp-8-CPT-cAMPS sodium

Cat. No.: HY-120994: FAQs
Data Sheet SDS Handling Instructions

Molarity Calculator

Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.

For research use only. We do not sell to patients.

Rp-8-CPT-cAMPS sodium Chemical Structure

CAS No. : 221905-35-7

Size	Price	Stock
500 μg	USD 450	Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Rp-8-CPT-cAMPS sodium:

Sp-8-CPT-cAMPS Get quote
Rp-8-CPT-cAMPS Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All PKA Isoform Specific Products:

View All Isoforms

PKA PKAR

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

PKA^[1]

In Vitro

Rp-8-CPT-cAMPS (100 μM; 15 min) blocks phosphorylation of VASP by 6-Bnz-cAMP and largely reduces VASP phosphorylation by forskolin and fenoterol^[2].
Rp-8-CPT-cAMPS (100 μM; 30 min) reduces GTP-loading of Rap1 by both 8-pCPT-2'-O-Me-cAMP and 6-Bnz-cAMP^[2].
Rp-8-CPT-cAMPS (100 μM; 30 min) largely diminishes the augmentation of bradykinin-induced IL-8 release by the PKA activator 6-Bnz-cAMP and the Epac activator 8-pCPT-2'-O-Me-cAMP^[2].
Rp-8-CPT-cAMPS (10 μM) inhibits the endothelium-dependent and -independent relaxation which induced by Venom in pre-contracted rat mesenteric artery rings^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

509.86

Formula

C₁₆H₁₄ClN₅NaO₅PS₂

CAS No.

221905-35-7

Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@](O[C@@](CO2)([H])[C@@]1([H])O[P@@]2([S-])=O)([H])N3C4=NC=NC(N)=C4N=C3SC(C=C5)=CC=C5Cl.[Na+]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMF : 30 mg/mL (58.84 mM; Need ultrasonic and warming)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9613 mL	9.8066 mL	19.6132 mL
5 mM	0.3923 mL	1.9613 mL	3.9226 mL
10 mM	0.1961 mL	0.9807 mL	1.9613 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Data Sheet (283 KB) SDS (251 KB) Handling Instructions (2659 KB)

References

[1]. Dostmann WR , et, al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. J Biol Chem. 1990 Jun 25;265(18):10484-91. [Content Brief]

[2]. Roscioni SS, et, al. PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir Res. 2009 Sep 29;10(1):88. [Content Brief]

[3]. Chaisakul J, et, al. In vivo and in vitro cardiovascular effects of Papuan taipan (Oxyuranus scutellatus) venom: Exploring "sudden collapse". Toxicol Lett. 2012 Sep 3;213(2):243-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMF	1 mM	1.9613 mL	9.8066 mL	19.6132 mL	49.0331 mL
	5 mM	0.3923 mL	1.9613 mL	3.9226 mL	9.8066 mL
	10 mM	0.1961 mL	0.9807 mL	1.9613 mL	4.9033 mL
	15 mM	0.1308 mL	0.6538 mL	1.3075 mL	3.2689 mL
	20 mM	0.0981 mL	0.4903 mL	0.9807 mL	2.4517 mL
	25 mM	0.0785 mL	0.3923 mL	0.7845 mL	1.9613 mL
	30 mM	0.0654 mL	0.3269 mL	0.6538 mL	1.6344 mL
	40 mM	0.0490 mL	0.2452 mL	0.4903 mL	1.2258 mL
	50 mM	0.0392 mL	0.1961 mL	0.3923 mL	0.9807 mL